SG Americas Securities LLC Grows Stake in Axon Enterprise, Inc $AXON

SG Americas Securities LLC raised its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 56.2% in the first quarter, HoldingsChannel reports. The firm owned 26,112 shares of the biotechnology company’s stock after acquiring an additional 9,398 shares during the period. SG Americas Securities LLC’s holdings in Axon Enterprise were worth $11,090,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Axon Enterprise by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after buying an additional 53,060 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Axon Enterprise by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock valued at $1,265,657,000 after buying an additional 35,544 shares during the period. Baillie Gifford & Co. raised its holdings in shares of Axon Enterprise by 1,198.7% in the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after acquiring an additional 1,516,099 shares in the last quarter. Sands Capital Management LLC raised its holdings in shares of Axon Enterprise by 11.6% in the fourth quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after acquiring an additional 167,095 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in Axon Enterprise by 326.9% in the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after acquiring an additional 1,179,038 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Price Performance

AXON opened at $465.12 on Friday. The business’s 50-day moving average is $420.65 and its two-hundred day moving average is $482.08. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. The firm has a market capitalization of $37.49 billion, a PE ratio of 186.79, a price-to-earnings-growth ratio of 8.09 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The business had revenue of $807.35 million during the quarter, compared to the consensus estimate of $778.90 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm’s revenue was up 33.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.47 earnings per share. Research analysts anticipate that Axon Enterprise, Inc will post 1.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AXON has been the topic of several recent research reports. Citizens Jmp reiterated a “market outperform” rating and set a $700.00 target price on shares of Axon Enterprise in a report on Thursday. TD Cowen reduced their price target on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Barclays lowered their price target on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. JPMorgan Chase & Co. lifted their price objective on shares of Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Finally, Zacks Research raised shares of Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $712.75.

Insider Transactions at Axon Enterprise

In related news, insider Isaiah Fields sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $400.00, for a total transaction of $800,000.00. Following the completion of the transaction, the insider owned 52,813 shares in the company, valued at $21,125,200. The trade was a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, President Joshua Isner sold 13,000 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the sale, the president directly owned 169,125 shares of the company’s stock, valued at $82,609,106.25. The trade was a 7.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 38,989 shares of company stock worth $19,090,083. 4.20% of the stock is owned by corporate insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.